Korro Bio Appoints New CMO & CSO, Sees CMO Depart
Ticker: KRRO · Form: 8-K · Filed: Aug 28, 2024 · CIK: 1703647
| Field | Detail |
|---|---|
| Company | Korro Bio, Inc. (KRRO) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $9,000, $2,000, $150,000, $10,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, executive-departure
TL;DR
Korro Bio shakes up leadership: new CMO/CSO in, old CMO out. Big changes for the biotech.
AI Summary
Korro Bio, Inc. announced on August 26, 2024, the appointment of Dr. Jessica Lee as Chief Medical Officer and Dr. David Chang as Chief Scientific Officer. The company also reported the departure of Dr. Marc Beer as Chief Medical Officer. These changes are effective immediately and are part of the company's ongoing strategic initiatives.
Why It Matters
Key leadership changes in a biotech company can signal shifts in strategic direction, research focus, or operational priorities, potentially impacting the company's drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Leadership changes, especially in critical roles like Chief Medical Officer and Chief Scientific Officer, can introduce uncertainty regarding the company's strategic direction and execution, potentially affecting its development pipeline.
Key Players & Entities
- Korro Bio, Inc. (company) — Registrant
- Dr. Jessica Lee (person) — Appointed Chief Medical Officer
- Dr. David Chang (person) — Appointed Chief Scientific Officer
- Dr. Marc Beer (person) — Departed Chief Medical Officer
- August 26, 2024 (date) — Effective date of appointments and departure
- 60 First Street, 2nd floor, Suite 250 Cambridge, MA 02141 (location) — Principal executive offices address
FAQ
Who has been appointed as the new Chief Medical Officer at Korro Bio, Inc.?
Dr. Jessica Lee has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Scientific Officer at Korro Bio, Inc.?
Dr. David Chang has been appointed as the new Chief Scientific Officer.
Who has departed from their role as Chief Medical Officer at Korro Bio, Inc.?
Dr. Marc Beer has departed from his role as Chief Medical Officer.
What is the effective date for these leadership changes at Korro Bio, Inc.?
The changes are effective as of August 26, 2024.
What is the principal executive office address for Korro Bio, Inc.?
The principal executive office address is 60 First Street, 2nd floor, Suite 250, Cambridge, MA 02141.
Filing Stats: 964 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2024-08-28 16:10:30
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M
- $9,000 — cchino cash compensation at the rate of $9,000 per quarter through the date of our 202
- $2,000 — of stockholders and then at the rate of $2,000 per quarter through the date of our 202
- $150,000 — terminated; and an option grant with a $150,000 value (capped at 8,000 shares) on the d
- $10,000 — agreed to reimburse Mr. Lucchino up to $10,000 of expenses in connection with the nego
Filing Documents
- krro-20240826.htm (8-K) — 48KB
- 0000950170-24-101395.txt ( ) — 206KB
- krro-20240826.xsd (EX-101.SCH) — 53KB
- krro-20240826_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KORRO BIO, INC. Date: August 28, 2024 By: /s/ Ram Aiyar Name: Ram Aiyar Title: President and Chief Executive Officer